Vaxcyte, Inc.
PCVXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Vaxcyte, Inc. (PCVX) is listed under Biotechnology. With a market capitalization of $9.51B, it sits in mid-cap territory. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Market Cap
$9.51B
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
-8.49
EPS (TTM)
$-7.62
EPS (Fwd)
$-7.12
ROE
-36.5%
ROA
-22.6%
Cash
$1.49B
Total Debt
$115.4M
Free CF
-$485.8M
52W Change
35.6%
Annual Financials
Cash vs Debt
Where PCVX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PCVX finished 11.62% above its 150-day moving average ($57.05) and 13.07% above its 200-day moving average ($56.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PCVX overbought or oversold?
At the October 20, 2026 close, PCVX's RSI(14) was 58.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.49B in cash comfortably exceeding the $115.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$485.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, PCVX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PCVX.